Synapse - Maria Bromberg

Results (28)

Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy

Meeting Abstract

Wibmer, A. G.; Feldman, D. R.; Chen, C.; Bromberg, M.; Dinh, P. C.; Zheng, J.; Capanu, M.; Travis, L. B.; Vargas, H. A.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors

Journal Article

Funt, S. A.; McHugh, D. J.; Tsai, S.; Knezevic, A.; O'Donnell, D.; Patil, S.; Silber, D.; Bromberg, M.; Carousso, M.; Reuter, V. E.; more...
The Oncologist (2021)

Fulltext@MSK | Save

Paclitaxel, ifosfamide & cisplatin (TIP) as second-line therapy for germ cell tumors (GCT):Long-term follow-up and expansion cohort

Meeting Abstract

Gleeson, J. P.; Knezevic, A.; Bromberg, M.; Patil, S.; Sheinfeld, J.; Carver, B. S.; Jones, D. R.; Bains, M. S.; Bajorin, D. F.; Bosl, G. J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Germ cell tumor molecular heterogeneity revealed through analysis of primary and metastasis pairs

Journal Article

Cheng, M. L.; Donoghue, M. T. A.; Audenet, F.; Wong, N. C.; Pietzak, E. J.; Bielski, C. M.; Isharwal, S.; Iyer, G.; Funt, S.; Bagrodia, A.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

Causes and patterns of mortality in patients with lethal germ cell tumor (GCT)

Meeting Abstract

Hamid, A.; Funt, S. A.; Markt, S. C.; Bromberg, M.; O'Donnell, D.; Adra, N.; Taza, F.; Albany, C.; Krailo, M. D.; Frazier, A. L.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Detailed evaluation of hearing loss (HL) associated with high-dose (HD) carboplatin for salvage treatment of germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Knezevic, A.; Wilson, K.; Bromberg, M.; Budnick, A.; McHugh, D. J.; Larsen, E.; Bajorin, D. F.; Motzer, R. J.; Tonorezos, E. S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save